Skip to content

Oruka Therapeutics, Inc. ORKA Number of reportable segments

Number of reportable segments at other companies

Insmed logo
InsmedINSM

Other financials

Income statement

See full
Revenue-
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$5.03B+533%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0.0×
Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NumberOfReportableSegments.

The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s number of reportable segments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s number of reportable segments?
Oruka Therapeutics, Inc. (ORKA) reported number of reportable segments of 1 in Q1 2026.
What does number of reportable segments mean?
The total count of distinct business units or geographic areas for which the company reports separate financial information. This metric provides insight into the organizational structure and the diversity of the company's operations. A higher number indicates a more complex, diversified business model, while a lower number suggests a more focused operational strategy.